VERALOX THERAPEUTICS, INC
VLX-1005, a first-in-class 12-lipoxygenase (12-LOX) inhibitor molecule for type 1 diabetes
- Sector
- Biotech
- Headquarters
- FREDERICK, MD
- Founded
- 2018
- Latest Form D
- $24M, Jun 2023
- Total capital
- $40.5M
- Federal grants
- $619K
- 2 awards · 2018–2019
- Rank in peer group#144 of 502
- Private capital raised
- $39.9M
- 3 Form D · last Jun 2023
- 40 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 7 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$24M
- Private capital raisedForm D · SEC · 2nd filing$14.4M
- Federal grantHealth and Human S · Phase I · Novel therapeutic for treatment of type 1 diabetes$300K
- Private capital raisedForm D · SEC · 1st filing$1.5M
- Federal grantHealth and Human S · Phase I · Development of a 12-LOX inhibitor for heparin induced thrombocytopenia and thrombosis$319K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
8months
from VERALOX THERAPEUTICS, INC’s first federal award to its first private round.
- First federal award · Sep 2018
- Health and Human S · $319K
- First Form D · May 2019
- $1.5M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grants#144 · top 29%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alex MartinDirectorNamed in SEC Form D filings
- Benjamin W. ScruggsDirectorNamed in SEC Form D filings
- Christopher W. GagliardiDirectorNamed in SEC Form D filings
- David W. MaloneyExecutive Officer, DirectorNamed in SEC Form D filings
- Jamie StiffDirectorNamed in SEC Form D filings
- Jeffrey W. StrovelExecutive Officer, DirectorNamed in SEC Form D filings
Show all 11 people
- Jonathan W. BehrDirectorNamed in SEC Form D filings
- Jonathan MowExecutive Officer, DirectorNamed in SEC Form D filings
- Katie W. ElliasDirectorNamed in SEC Form D filings
- Matthew W. BoxerExecutive Officer, DirectorNamed in SEC Form D filings
- Megan KrenchDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 7- PendingCompositions And Methods Of Use To Treat 12-LIPOXYGENASE (12-LOX) Mediated DiseasesUSPTOApplication PCTUS2024035216
- PendingMethods For Treating Heparin-induced ThrombocytopeniaUSPTOApplication 63570574
- Pending12-LIPOXYGENASE Inhibitors For The Treatment Of LupusUSPTOApplication PCTUS2023079411
Show all 7 patent records
- Compositions And Methods Of Use To Treat 12-LIPOXYGENASE (12-LOX) Mediated DiseasesApplication PCTUS2024035216Pending
- Methods For Treating Heparin-induced ThrombocytopeniaApplication 63570574Pending
- 12-LIPOXYGENASE Inhibitors For The Treatment Of LupusApplication PCTUS2023079411Pending
- Oral Pharmaceutical Formulations Containing 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) Benzenesulfonamide DerivativesApplication PCTUS2023078471Pending
- Compositions And Methods Of Use To Treat 12-LIPOXYGENASE (12-LOX) Mediated DiseasesApplication PCTUS2022081779Pending
- Aqueous Parenteral Pharmaceutical Formulations Containing 4- ((2-HYDROXY-3-METHOXYBENZYL)AMINO) Benzenesulfonamide DerivativesApplication PCTUS2022081645Pending
- Compositions And Methods Of Use To Treat 12-LIPOXYGENASE (12-LOX) Mediated DiseasesApplication 19496351Pending
Related companies, and why
- Reviva Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Turn Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- Codebreaker Tx, Inc.Similar federal contract value in Biotech · null in contracts
- NEUROP, INC.Similar federal contract value in Biotech · null in contracts
- Axiom Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- FluidForm Bio, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .